Title:
POLYPEPTIDE COMPOUND AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2021/143810
Kind Code:
A1
Abstract:
Disclosed are a polypeptide compound and the use thereof, dual or triple agonist polypeptide drugs that activate a glucagon-like peptide-1 receptor and optionally activate a glucose-dependent insulinotropic polypeptide receptor and a glucagon receptor, and the use thereof for the treatment of metabolic syndrome.
More Like This:
Inventors:
HUANG LIANG (CN)
CAO CHUNLAI (CN)
DENG HUIXING (CN)
ZHOU CUI (CN)
LIU HEDONG (CN)
XIE XIN (CN)
HE XIUYI (CN)
YANG XIAOCHUN (CN)
CAO CHUNLAI (CN)
DENG HUIXING (CN)
ZHOU CUI (CN)
LIU HEDONG (CN)
XIE XIN (CN)
HE XIUYI (CN)
YANG XIAOCHUN (CN)
Application Number:
PCT/CN2021/072049
Publication Date:
July 22, 2021
Filing Date:
January 15, 2021
Export Citation:
Assignee:
ZHUHAI UNITED LABORATORIES CO LTD (CN)
International Classes:
C07K14/605; A61K38/26; A61P5/48
Domestic Patent References:
| WO2017160669A1 | 2017-09-21 | |||
| WO2017189342A1 | 2017-11-02 |
Foreign References:
| CN103458920A | 2013-12-18 | |||
| CN103458920A | 2013-12-18 | |||
| CN103087175A | 2013-05-08 | |||
| CN102180963A | 2011-09-14 |
Other References:
EVERS ANDREAS, BOSSART MARTIN, PFEIFFER-MAREK STEFANIA, ELVERT RALF, SCHREUDER HERMAN, KURZ MICHAEL, STENGELIN SIEGFRIED, LORENZ M: "Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists Specifically Optimized for Multidose Formulations", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 61, no. 13, 12 July 2018 (2018-07-12), pages 5580 - 5593, XP055829008, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.8b00292
Attorney, Agent or Firm:
CHINA PATENT AGENT (HK) LTD. (CN)
Download PDF: